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A 13-year-old, poodle-mixed, male dog was referred to the oncology unit in our faculty’s small animal teaching hospital with the
problem of rapid recurrent MCT. The owner and the veterinarian would like to use a tyrosine kinase inhibitor (TKI) for the dog.
Therefore, fine-needle aspiration (FNA) was performed to collect theMCT cells and these cells were submitted to our laboratory for
the detection of internal-tandem-duplicated (ITD) mutation of exon-11 in c-kit, prior to the treatment. The aim of this paper is to
demonstrate the use of combinatorial protocol for the rapid evaluation of ITDmutation in MCT cells harvested by FNA. However,
there was no ITD-mutant exon-11 that had been observed in this case.
1. Introduction
Canine cutaneous mast cell tumors (MCT) are the second
most skin tumors found in dogs. The incidence is probably
medium to high in some breeds, such as boxer, bull dog,
pug, poodle, labrador retriever, and golden retriever. In
general, all MCT patients required an aggressive diagnosis
and therapy because the progression of disease is very rapid
[1]. Among obscured tumorigenesis of MCT, however, there
has been much information from various studies show-
ing that the mutation of exon-11, called internal-tandem-
duplication (ITD), of proto-oncogene, c-kit, is involved in
MCT formation. Principally, c-kit is a protein-coding gene
responsible for KIT (CD117) formation and it is usually
expressed in many cell species, such as normal mast cells,
melanocytes, and Purkinje cells including MCT cells [2].
KIT is a member of the receptor-tyrosine-kinases class
III (RTKs class III). It consists of three functioning domains,
extracellular (ectodomain), transmembrane (TM), and intra-
cellular domains, respectively [3]. The intracellular domain
is further separated into two subsidiary portions; juxtamem-
brane encoded by exon-11 and kinase domains encoded
by the remaining exons. The function of KIT is triggered
when the ectodomain binds to the specific ligand, stem
cell factor (SCF), followed by KIT dimerization and cross-
autophosphorylation to tyrosine residues on the dimerized
KITs. The consequence is to activate the downstream-
signaling cascades, which are responsible for the growth and
proliferation as well as antiapoptosis of mast cells. In case
of MCT, ITD mutation of exon-11 results in the abnormally
autonomous KIT dimerization without any specific ligand
binding. This mechanism leads to uncontrollable autophos-
phorylation followed by MCT formation. Nevertheless, this
type of mutation also affects MCT therapy when a tyro-
sine kinase inhibitor (TKI), such as SU-11654, is used [4].
Therefore, the detection of ITD-mutant exon-11 is clinically
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important for MCT diagnosis and therapeutic planning.
However, a utilization of MCT cells collected by FNA for
the detection of ITD-mutant exon-11 has not recently been
reported anywhere.
The objective of this paper is to report the employment
of CD117 immunocytofluorescence and FACS-cell sorting for
rapid identification and isolation of MCT cells harvested by
FNA. In addition, we also demonstrate the usage of these cells
to diagnose ITD-mutant exon-11 by PCR in a recurrent MCT
case.
2. Case Presentation
A 13-year-old, poodle-mixed, male dog was referred to the
Oncology Clinic, Small Animal Teaching Hospital, Faculty
of Veterinary Science, Chulalongkorn University, with the
recurrent MCT-grade II (based on Patnaik histopathologic
grading) at the neck and the dorsomedial of the left palmar
(Figure 1). The dog was undertaken a surgical removal with
prophylactic chemotherapy along the year. However, the
treatment was ineffective and the progression of the disease
was rapidly advanced. Finally, the owner and the responsible
veterinarian planned to use a tyrosine kinase inhibitor (TKI)
in this case. However, the owner was unwilling to repeat a
skin biopsy for his dog. Hence, the previous tissue section
was sent to our laboratory for histopathology reevaluation
grounded on the novel 2-tier histopathologic grading system
[5] and the veterinarian exploited FNA to aseptically collect
the cell sample from the mass at the left palmar (Figure 1) for
investigating ITD-mutant exon-11.
To identify MCT-cell population, a few drops of neoplas-
tic cells from FNA were smeared on a clean silane-coated
glass slide. The cells were then preserved in 4∘C cold acetone
for a minute and they were incubated by 1% bovine serum
albumin (BSA) for 30 minutes at room temperature to block
nonspecific proteins. The tumor cells were further incubated
with PE-conjugated mouse monoclonal anti-human CD117
antibodies (Clone Y.B5.B8, Becton and Dickinson, USA) for
30minutes at the concentration of 1 : 100 at room temperature
in a dark chamber. The specificity of the antibodies was
already approved by our laboratory in our previous study.
The MCT cells were counterstained by 4󸀠,6-Diamidino-
2-Phenylindole (DAPI, Invitrogen, USA), and they were
visualized under a fluorescent microscope with 575 nm light
source. In this study, we also used normal mast cells and
histiocytoma cells prepared by the same method, as the
positive and negative controls, respectively.
For ITD-mutation assessment, the neoplastic cells were
firstly purified using FACS-cell sorting. Briefly, the cells
previously harvested by FNA were resuspended in 500𝜇L
sterile PBS. The erythrocytes were eradicated from the cell
suspension by adding 10mL of BD Facs lysing solution for
10 minutes (Becton and Dickinson, USA). Further, the cell
suspension was centrifuged at 4,000×g for 5 minutes and the
supernatant was discarded after centrifugation.The cell pellet
was then added by 500𝜇L BD FacsPerm solution (Becton
and Dickinson, USA) for 10 minutes to increase membrane
permeability, and it was washed by PBS twice. The neoplastic
Figure 1:The location of MCTmass at the dorsomedial plane of the




















Figure 2: The dot plot of CD117-immunopositive MCT cells in this
case was drawn back by the software. The MCT cells were gated
electronically and were harvested from the cells presenting above
the baseline, at the quadrant II (upper-right) of dot plot.
cells were incubated, in the dark chamber, by 100 𝜇L of PE
directly conjugated mouse monoclonal anti-human CD117
antibodies (Clone Y.B5.B8, Becton and Dickinson, USA),
at concentration of 1 : 200 for 20 minutes. The cells were
washed and centrifuged again at 4,000×g for 5 minutes and
the supernatant was then decanted. The cell sediment was
resuspended in 10mL of sterile PBS. Data acquisition was
performed using BD-FACScalibur Cell Sorter with BD Cell-
Sorting software system (Becton and Dickinson, USA) and
the CD117-immunopositive cells were gated from the cells
presenting above the threshold line, at the quadrant II of dot
plot (Figure 2). The cells were sorted out and harvested into
a collecting tube for PCR analysis. The monoclonal IgG was
used as the isocontrol for establishing the threshold line on
the dot plot.
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The genomic DNA (gDNA) of FACS-sorted neoplastic
cells was extracted using the commercial DNA-isolation kit
(Mobio,USA) and its concentrationwas computed usingUV-
spectrophotometry. The forward and reverse primers were
designed from 5󸀠 end of exon-11 and 3󸀠 end of intron-11 of c-
kit, respectively [6, 7].The sequence of forward primerwas 5󸀠-
CCA TGT ATGAAG TACAGTGGAAG-3󸀠 and the reverse
primer was 5󸀠-GTT CCCTAAAGTCAT TGT TACACG-3󸀠,
respectively.
The PCR cocktail was prepared in a flat-capped PCR tube
(Axygen, USA). 25𝜇L of PCR mixer consisted of 1.5 𝜇L of







buffer solution (DreamTaq, Fermantas,
USA), 3 𝜇L of 20mMMgCl
2
solution (Fermantas, USA), 1 𝜇L
of 2mM dNTP solution (Fermantas, USA), 0.5𝜇L of Taq
polymerases (DreamTaq, Fermentas, USA), 2𝜇L of 10mM
forward primers solution, 2𝜇L of 10mM reverse primers
solution, 4 𝜇L of purified DNA template, and 9.5𝜇L of
nuclease-free water (Mobio, USA). The DNA template was
amplified in the thermocycler (G-Storm,USA)with the batch
of programmatic temperatures of 95∘C for 5 minutes for
initial DNA denaturation; 40 cycles of 95∘C 1 minute for
cyclic DNA denaturation, 57∘C for 1 minute for cyclic DNA
annealing, and 72∘C for 1 minute for cyclic DNA extension;
and 72∘C for 5 minutes for complete DNA elongation [8].
DEPC water was used as the negative control in this study.
Meanwhile, gDNA of non-ITD and ITD-mutant exon-11 cells
prepared by College of Veterinary Medicine, Michigan State
University, USA, was utilized as the normal and positive
controls, respectively. In addition, we also used one positive
specimen prepared by the same protocols for collating the
result with this case.
Ultimately, the amplicons were separated using 2% EtBr-
mixed agarose gel electrophoresis at 100V for 40 minutes.
The amplicons were visualized by the gel documentation
apparatus (Bio-Rad, USA). The information was analyzed
by the computerized software system, Quantity One version
4.6.9 (Bio-Rad, USA), and transformed into JPEG-imaging
system using Microsoft Paint (Microsoft, USA).
Upon the study results, the histopathologic section
was reclassified as the high-grade MCT. Moreover, CD117
immunocytofluorescence clearly ratified the MCT-cell pop-
ulation in the aspirate. All tumor cells strongly exhibited
CD117 immunopositivity on their plasma membranes and
cytoplasm; meanwhile, their nuclei were stained blue by
DAPI, as shown in Figure 3. It is noteworthy to notice that
there were some CD117-immunonegative cells presenting in
the smear.These cells were not MCT cells as compared to the
negative control.
In addition, approximately 400,000 FNA-MCT cells were
harvested by FACS-cell sorting. The genomic DNA of these
cells was extracted using the aforementioned protocol and its
concentration was 156.65𝜇g/mL. There was no ITD mutant
exon-11 of c-kit observed in this case (Figure 4). The single
band of PCR product in this case was 191 bp compared to
the positive control and the positive specimen (2 product
bands at 191 bp and 250 bp, resp.) and the normal control
(191-bp).
Figure 3: CD117 immunocytofluorescence has confirmed MCT
subpopulation in the aspirate.The nuclei were stained blue byDAPI.
Notably, some cells were non-MCT cells because of lack of CD117
immunopositivity in their cytoplasm and on plasma membranes.
Figure 4:The 191 bp of PCR product in this case (in specimen lane)
substantially suggested that there was no ITD-mutant exon-1, as well
as in the normal control. Notably, the PCR products of the positive
control and the positive specimen from the other case consisted of 2
distinct bands at 191 bp and 250 bp (ITD).
3. Discussion
The ITD-mutant exon-11 in c-kit is seemingly essential
in MCT tumorigenesis as this mutation has been widely
studied [3, 6, 8]. Moreover, the ITD-mutation of exon-11
also influences a TKI administration. Basically,MCT patients
who possess ITD-exon-11, usually respond to a TKI therapy
greater than nonmutational patients [4].
In this study, we have demonstrated an alterna-
tive protocol for rapid MCT diagnosis. CD117-immunocy-
tofluorescence could enhance our ability for precise
identification of MCT cells. Particularly, in high-grade MCT
in which the neoplastic cells are usually pleomorphic and
their morphology might mimic other neoplastic cells, such
as round-cell tumor cells. Moreover, FACS-cell sorting could
rapidly facilitate us to purify the MCT population. These
MCT cells were a good source of cells which could be utilized
to detect the ITD-mutant exon-11, at least in this case. A rapid
diagnosis of ITD-mutant exon-11 may help a veterinarian to
decide himself on a TKI usage.
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In this case, we supposed that this case should have
mutant exon-11 due to an aggressive behavior of the neo-
plasm. However, ITD-mutant exon-11 was not observed
in this case. This might suggest that the mutant exon-11
might not associate with histopathologic grade, but it should
associate with the recurrence rate. However, we strongly
recommend that a further study based on our combinatorial
protocol must be performed in a large population to ensure
the advantage of this protocol, before this combinatorial
method will be used as a standard protocol for rapid MCT
diagnosis in the future.
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